In drug-induced, immune-mediated hepatitis, interleukin-33 reduces hepatitis and improves survival independently and as a consequence of FoxP3+ T-cell activity
Merylin Cottagiri, Maeva Nyandjo, Matthew Stephens, Joel J. Mantilla, Hirohisa Saito, Ian R. Mackay, Noel R. Rose, Dolores B. Njoku
Dive into the research topics of 'In drug-induced, immune-mediated hepatitis, interleukin-33 reduces hepatitis and improves survival independently and as a consequence of FoxP3+ T-cell activity'. Together they form a unique fingerprint.